Hormonal
SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalizations, and kidney disease progression in patients with type 2 diabetes, regardless of baseline glycemic control.
If you have Type 2 Diabetes and heart disease, heart failure, or kidney issues, ask your doctor about SGLT2 inhibitors (like Jardiance, Farxiga, or Invokana). These drugs protect your heart and kidneys directly, offering significant benefits even if your blood sugar is already well-controlled. They are now a standard part of care for high-risk patients, regardless of whether they lower blood sugar significantly.
The SGLT2 inhibitors have also gained great attention as a new class of therapies for heart failure and for CKD, irrespective of DM status... empagliflozin has shown benefit for reducing HFH and CVD death both in persons with HF with reduced ejection fraction (HFrEF) ... and preserved ejection fraction HF (HFpEF) ... both in those with and without diabetes.
Why this rating
Based on multiple large-scale randomized controlled trials (EMPA-REG, CANVAS, DECLARE) cited in the review.
Source
Cardiodiabetology: newer pharmacologic strategies for reducing cardiovascular disease risks
Nathan D. Wong · Canadian Journal of Physiology and Pharmacology · 2022
DOI 10.1139/cjpp-2022-0065
More from this paper
- GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with Type 2 Diabetes, with specific benefits on stroke and weight loss.Strong
- Icosapent ethyl (pure EPA) reduces cardiovascular events in patients with Type 2 Diabetes and elevated triglycerides who are already on statin therapy.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →